摘要目的 通过检测拉米夫定治疗患者血清中的乙型肝炎病毒大蛋白(HBV-LP),同时检测乙型肝炎病毒DNA(HBV-DNA)载量,探讨拉米夫定治疗过程中HBV-LP与HBV-DNA的关系,观察乙型肝炎病毒大蛋白用于评估拉米夫定抗病毒治疗的应用效果.方法采用酶联免疫吸附试验(ELISA)的方法对HBV-LP进行检测;采用荧光定量PCR方法对HBV-DNA进行检测.结果抗病毒治疗有效的患者HBV-DNA和HBV-LP下降趋势一致,HBV-LP出现阴转的时间要晚3个月于HBV-DNA阴转;抗病毒治疗无效的患者HBV-DNA和HBV-LP都是始终没有出现阴转;抗病毒治疗效果反复组中患者HBV-LP始终没有出现阴转,HBV-DNA则暂时阴转.结论拉米夫定抗病毒治疗过程中动态检测乙型肝炎病毒大蛋白可用于评估抗病毒治疗效果.

abstractsObjective To study the correlation between serum hepatitis B virus large surface protein (HBV-LP)and hepatitis B virus DNA (HBV-DNA) load in hepatitis B patients treated with lamivudine, and the application of serum HBV-LP measurement in evaluation of lamivudine therapeutic effect and end point judgement.Methods HBV DNA was detected by fluorescent quantitative PCR (FQ-PCR), serum HBV-LP was detected by enzyme linked immunosorbent assay (ELISA). Results Both HBV-DNA and HBV-LP decreased in patients responding to lamivudine therapy, and HBV-LP turned negative 3 months later than HBV-DNA. In patients resistant to lamivudine therapy, neither HBV-DNA nor HBV-LP turned negative. In patients whose symptoms relapsed, HBV-LP didn't turn negative, while HBV-DNA was undetectable only transitorily. Conclusion Measuring serum HBV-LP dynamically can be useful in evaluation of lamivudine therapeutic effect.